Eton Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2018. Amounts are in U.S. dollars; financial statement amounts are in thousands unless noted. Eton is an early-stage specialty pharmaceutical company developing prescription products, primarily using the FDA’s 505(b)(2) pathway. It had no product revenue and had not begun revenue-producing operations.
Financial performance and position
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Comparable 2017 period |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $1,544 | $1,564 | $4,525 | $3,067 |
| General and administrative expense | $830 | $1,206 | $3,510 | $1,887 |
| Total operating expenses | $2,374 | $2,770 | $8,035 | $4,954 |
| Net loss | $2,910 | $2,802 | $9,010 | $4,986 |
| Net loss attributable to common stockholders | $3,639 | $3,493 | $11,167 | $5,768 |
| Loss per common share, basic and diluted | $0.65 | $1.00 | $2.40 | $1.69 |
The 2017 nine-month comparison is for the period from the company’s April 27, 2017 inception through September 30, 2017, not a full nine months. Eton had no gross profit or operating margin because it generated no revenue.
- Cash flow: Net cash used in operations was $6.371 million for the first nine months of 2018, versus $3.650 million from inception through September 30, 2017. Capital spending used $182,000; financing provided no cash during the 2018 period.
- Liquidity: Cash and cash equivalents were $6.603 million at September 30, 2018, down from $13.156 million at December 31, 2017. Working capital was $5.606 million. Total assets were $7.525 million.
- Liabilities and equity: Total liabilities were $2.774 million, including $1.197 million of current liabilities and a $1.577 million warrant liability. The filing reports no borrowings or cash interest paid. Series A redeemable convertible preferred stock was carried as temporary equity at $21.161 million; accumulated deficit was $19.806 million.
Material changes and significant events
- Q3 operating expenses declined $396,000 from Q3 2017, primarily reflecting lower G&A costs, including reduced stock-based consulting and legal and professional fees; higher personnel costs partly offset the reduction. Net loss nevertheless increased slightly, partly due to a larger warrant fair-value expense.
- For the nine-month periods, operating expenses increased $3.081 million and net loss increased $4.024 million. Management attributed higher costs to a full nine months of operations in 2018 versus a partial start-up period in 2017, increased compensation and board costs, and expanded product development.
- The warrant liability’s fair value increased by $1.057 million in the first nine months of 2018, recorded as expense. Its reported balance rose from $520,000 at year-end 2017 to $1.577 million at September 30, 2018. After the IPO fixed the shares issuable under the warrant, the liability was reclassified to additional paid-in capital.
- After quarter-end, Eton completed an IPO, selling 4.14 million shares at $6.00 each and receiving $22.603 million in net proceeds. Series A preferred shares converted into 7,248,948 common shares. The filing describes the IPO as completed in November 2018; it gives November 13 as the closing date in one section and November 15 as the date proceeds were received in another.
Outlook, risks, and contingencies
- Management estimated that September cash plus IPO proceeds would fund operating and capital requirements for at least 24 months from issuance of the financial statements, assuming spending can be managed as planned. It cautioned that capital could be used sooner; delays in development or regulatory approval could require additional financing, spending reductions, or discontinued operations.
- Two candidates had been filed with the FDA and were under review: an ANDA for EM-100 and an NDA for DS-300. No candidate had received marketing approval. Management expected continued substantial development and public-company costs and ongoing losses.
- Key risks include regulatory or clinical delays or failure, uncertainty around 505(b)(2) eligibility, competition and limited patent protection, reliance on contract manufacturers and CROs, reimbursement and commercialization challenges, and potential future financing needs.
- The company disclosed agreements involving entities in which its CEO has ownership interests, including licensing, milestone, royalty or profit-sharing arrangements. It stated that it believes the terms approximate arm’s-length terms. No material litigation was reported as pending or threatened.
- A separate injectable pentoxifylline candidate was suspended indefinitely after FDA discussions indicated that required clinical trials would be unusually costly. A product licensed from Imprimis was also returned in 2018 after Eton determined it was not viable for its portfolio.
- Disclosure controls and procedures were assessed as effective for the quarter. The filing reports no material change in internal control over financial reporting during the period.
Important facts for investors to verify
- Current FDA review status, remaining requirements, and expected milestones for EM-100 and DS-300, as well as progress across the broader pipeline.
- Actual cash burn and whether the stated 24-month runway remains achievable against development plans and post-IPO expenses.
- The economic and governance terms of CEO-related-party agreements, including contingent payments, royalties, and profit shares.
- Post-IPO fully diluted share count and potential dilution from preferred-stock conversion, warrants, options, and equity awards.
- The assumptions behind the Level 3 warrant valuation and the effect of the IPO-related accounting and preferred-stock conversion on subsequent-period results.